Peru Clinical Evaluation Report for Class III-IV Devices: Requirements and Strategy 2026

Regulatory information verified as of October 29, 2026

1. Key takeaways

The Clinical Evaluation Report (CER) for Class III/IV devices in Peru is an evidence-synthesis argument, not an alias for a clinical trial report. Whether it passes technical review depends on whether the evidence set completely covers the declared intended use, not on whether a local clinical trial is attached. The benchmark is the set of essential principles (Principios Esenciales de Seguridad y Desempeño) established by D.S. N° 003-2020-SA, published on 2020-02-06, together with the inherent risk of the product itself; the procedural clock for Class III/IV is 66 working days, with an assessment cap of 90 calendar days. The working rule that follows is to narrow claims and thicken evidence: at this risk tier, reviewers tolerate less slack in the argumentation, and every claimed indication without matched evidence is a standing invitation for an Observaciones letter.

2. Legal basis

Regulatory information verified as of October 29, 2026.

3. Expert insights

Insight 1: the CER is an argument chain, not a data set.

The CER is organized around claim — evidence — appraisal: first define the declared intended use and clinical claims, then match evidence to each claim, then appraise whether the evidence suffices. The three evidence sources each hold a defined position: equivalence comparison to a predicate device transfers existing clinical experience to the declared product; literature fills in long-term safety and rare events; the sponsor’s own clinical trial covers what migration cannot resolve. Mechanically, the reviewer examines not the quantity of evidence but the coverage relation between claims and evidence: a CER claiming five indications while arguing two is more likely to be returned than a CER claiming two with full argument, because uncovered claims are visible defects on the face of the document.

Insight 2: the equivalence argument is the link most often lost.

Equivalence to a predicate device is typically argued across three dimensions: technical, biological and clinical. The technical dimension covers design, materials and performance parameters; the biological dimension covers tissue response to body contact; the clinical dimension covers use, users and conditions of use. The failures concentrate in familiar places: a declared product changes material supplier while the old equivalence conclusion is reused, software algorithms are upgraded while the file claims the hardware is identical, or the sterilization method changes without re-evaluating biocompatibility. Any dimensional difference without bridging data breaks the equivalence chain, and the center of gravity of the CER must then shift to literature or the sponsor’s own clinical data.

Insight 3: the high-risk tier changes the center of gravity of proof, not its form.

Class III/IV carries an assessment cap of 90 calendar days under Art. 136 of D.S. N° 016-2011-SA and a procedural clock of 66 working days under the current TUPA (specific article numbers pending verification; official publications prevail). The higher level does not impose a mechanical requirement to run a clinical trial; it reduces the tolerance for thin evidence: an argument acceptable on a low-risk product will be challenged on a high-risk one for insufficient margin. The writing strategy for a Class III/IV CER is therefore to narrow claims and thicken argument rather than broaden claims and dilute it.

Insight 4: the CER and post-market vigilance are two ends of one evidence chain.

R.M. N° 539-2016/MINSA, published on 2016-07-27, requires serious adverse events to be reported within 24 hours and moderate and mild suspected adverse events within 20 calendar days. The residual risks identified in the CER are precisely the objects the vigilance system must monitor; where the two operate independently, the file asserts acceptable risk while the vigilance plan contains no corresponding monitoring item. Converting the residual-risk list directly into vigilance monitoring items is the most economical way to close that loop and keeps the safety story consistent from pre-market review through post-market reporting.

4. Practical recommendations

1. Fix claims before hunting evidence: list the intended use and clinical claims line by line, delete any statement without supporting evidence, and prefer narrowing over leaving gaps.
2. Write the equivalence chain dimension by dimension: give a comparison table and a difference conclusion for the technical, biological and clinical dimensions, and attach bridging data wherever a difference exists.
3. Leave a searchable trail for literature: record the search strings, databases, time ranges and screening flow so the reviewer can verify completeness.
4. Route clinical trials through the authorization of D.S. N° 021-2017-SA, published on 2017-06-30: INS approves protocol and results, DIGEMID approves the investigational product, and the two approval lines advance in sequence.
5. Convert residual risks into vigilance items: map the residual risks in the CER conclusion onto the Tecnovigilancia monitoring plan, in a form executable against the 24 hours and 20 calendar days deadlines.
6. Front-load the deficiency contingency: Class III/IV run on the 66 working days clock with a 30 working days response window, so self-check every contestable point before submission.
7. Keep the secondary announcement out of the dossier: the number and date of Comunicado N° 009-2026 (2026-07-05) come from industry databases and are pending first-hand verification; use it as internal reference only.

5. Verification checklist

□ The essential-principles conformity argument has been compiled under D.S. N° 003-2020-SA and incorporated into the technical report

□ The intended use and clinical claims have been listed line by line, with confirmed evidence coverage for each

□ The three-dimensional equivalence comparison has been completed, with bridging data prepared for differences

□ Literature search strings, databases, time ranges and screening flow have been recorded

□ It has been confirmed that any clinical trial has obtained the corresponding INS and DIGEMID approvals under D.S. N° 021-2017-SA

□ Residual risks have been mapped to the Tecnovigilancia monitoring plan (24 hours / 20 calendar days)

□ The 66 working days procedural clock and 30 working days response window have been registered

□ Secondary-source announcements have been excluded from submission documents

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides registration support in Peru for manufacturers, importers and authorized representatives, including clinical evaluation reporting for Class III/IV devices. Contact: info@grzanglobal.com